A Phase 3 study evaluating ianalumab for Warm Autoimmune Hemolytic Anemia (wAIHA) reached primary completion on 2026-02-20. This milestone indicates that the final data for the primary outcome measure has been collected from all participants in the trial.
Background
The study investigated ianalumab for patients with warm autoimmune hemolytic anemia (wAIHA). This condition affects individuals who have previously failed at least one line of treatment, highlighting the need for new therapeutic options in this population.
Trial design
The Phase 3 study (NCT05648968) enrolled 90 participants with warm autoimmune hemolytic anemia (wAIHA). The trial's primary purpose is to evaluate the efficacy and safety of ianalumab compared to placebo. Participants in the study had previously failed at least one line of treatment for their condition. The trial is currently listed as ACTIVE_NOT_RECRUITING.
What this means
The primary completion of this Phase 3 study for ianalumab in warm autoimmune hemolytic anemia signifies a critical step towards potential regulatory submission. While no efficacy or safety results have been released yet, this milestone confirms that all necessary data for the primary endpoint has been collected. Clinicians and patients will await the full analysis and publication of these results to understand the potential role of ianalumab in treating previously treated wAIHA.
Source
The information regarding this trial's primary completion was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for the study NCT05648968, titled "A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia", was posted on 2026-02-20 on clinicaltrials.gov.